BIIB vs GILD
Biogen (BIIB) and Gilead Sciences (GILD) compared side by side. Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $37.0B for Biogen, about 5.2 times the size. BIIB returned +67.0% over the past year including dividends, versus +32.4% for GILD, through October 23, 2026..
Head to head
| Metric | BIIB | GILD |
|---|---|---|
| Market cap | $37.0B | $193.5B |
| P/E (TTM) | 44.5x | — |
| Forward P/E | 15.2x | 15.6x |
| Revenue (TTM) | $10.0B | $30.5B |
| Revenue growth | 3.4% | 10.2% |
| Gross margin | 78.3% | 79.6% |
| Operating margin | 25.1% | 33.7% |
| Free cash flow | $2.5B | $12.9B |
| Dividend yield | None | 2.10% |
| 1-year return | +67.0% | +32.4% |
| 5-year return (annual) | -1.1% | +22.6% |
| Max drawdown | -90% | -71% |
| FI Handbook grade | C | B- |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
$10.0K
$20.0K
20222023202420252026
BIIB vs GILD FAQ
Which is bigger, BIIB or GILD?
Gilead Sciences (GILD) is larger, with a market cap of $193.5B versus $37.0B for Biogen, about 5.2 times the size.
Which stock performed better over the past year, BIIB or GILD?
BIIB returned +67.0% over the past year including dividends, versus +32.4% for GILD, through October 23, 2026.
Which pays a higher dividend, BIIB or GILD?
GILD yields 2.10%; BIIB does not pay a dividend.
Full pages: Biogen · Gilead Sciences